NasdaqGS - Delayed Quote USD

Edgewise Therapeutics, Inc. (EWTX)

16.17 +0.23 (+1.44%)
At close: 4:00 PM EDT
16.17 0.00 (0.00%)
After hours: 4:20 PM EDT

Key Executives

Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
NameTitlePayExercisedYear Born
Dr. Peter A. Thompson FACP, M.D. Co-Founder & Independent Chairman 73k -- 1960
Dr. Kevin Koch Ph.D. President, CEO & Director 913.1k -- 1960
Dr. Badreddin Edris Ph.D. Co-Founder & Independent Director 40k -- 1988
Dr. Alan J. Russell Ph.D. Co-Founder, Chief Scientific Officer & Director 657.52k -- 1970
Dr. Joanne M. Donovan M.D., Ph.D. Chief Medical Officer 695.48k -- 1957
Mr. R. Michael Carruthers Chief Financial Officer 386.01k -- 1958
Mr. John R. Moore General Counsel -- -- 1964
Dr. Behrad Derakhshan Ph.D. Chief Business Officer 575.53k -- 1980
Dr. Marc Semigran M.D. Chief Development Officer -- -- 1957

Edgewise Therapeutics, Inc.

1715 38th Street
Boulder, CO 80301
United States
720 262 7002 https://www.edgewisetx.com
Sector: 
Healthcare
Industry: 
Biotechnology
Full Time Employees: 
88

Description

Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders that is in Phase I clinical trials. In addition, it develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was incorporated in 2017 and is headquartered in Boulder, Colorado.

Corporate Governance

Edgewise Therapeutics, Inc.’s ISS Governance QualityScore as of April 1, 2024 is 9. The pillar scores are Audit: 7; Board: 9; Shareholder Rights: 8; Compensation: 9.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Recent Events

Upcoming Events

May 09, 2024 - May 13, 2024
Edgewise Therapeutics, Inc. Earnings Call

Related Tickers

CGEM Cullinan Therapeutics, Inc.
25.30
+31.43%
 
GLUE Monte Rosa Therapeutics, Inc.
5.33
-2.20%
 
TYRA Tyra Biosciences, Inc.
15.67
+3.71%
 
ANRO Alto Neuroscience, Inc.
14.18
+0.35%
 
TRDA Entrada Therapeutics, Inc.
12.45
+0.73%
 
KYMR Kymera Therapeutics, Inc.
33.37
+0.06%
 
SNDX Syndax Pharmaceuticals, Inc.
21.06
+2.38%
 
LBPH Longboard Pharmaceuticals, Inc.
19.72
+2.44%
 
LXEO Lexeo Therapeutics, Inc.
12.50
+2.80%
 
DYN Dyne Therapeutics, Inc.
24.73
+4.37%